CHECKPOINT ATHERO: developing immune checkpoint-based therapeutics for atherosclerosis

CHECKPOINT ATHERO: developing immune checkpoint-based therapeutics for atherosclerosis

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Lutgens, E, Mulder, WJM, Monaco, C
Άλλοι συγγραφείς:	CHECKPOINT ATHERO consortium
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Oxford University Press 2023

Παρόμοια τεκμήρια

Risk factors in coronary atherosclerosis athero-inflammation: the meeting point
ανά: Altman Raul
Έκδοση: (2003-07-01)

Immune checkpoints as therapeutic targets in autoimmunity
ανά: Paluch, C, κ.ά.
Έκδοση: (2018)

Acute coronary disease Athero-Inflammation: Therapeutic approach
ανά: Altman Raul
Έκδοση: (2003-06-01)

The ATHERO-AF Study
ανά: Michael D. Ezekowitz, MBChB, DPhil, κ.ά.
Έκδοση: (2024-08-01)

Immune Checkpoints as Therapeutic Targets in Autoimmunity
ανά: Christopher Paluch, κ.ά.
Έκδοση: (2018-10-01)

Cell-specific and athero-protective roles for RIPK3 in a murine model of atherosclerosis
ανά: Sarah Colijn, κ.ά.
Έκδοση: (2020-01-01)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
ανά: Pal Maurovich-Horvat, κ.ά.
Έκδοση: (2023-07-01)

Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
ανά: Esther Lutgens, κ.ά.
Έκδοση: (2022-09-01)

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
ανά: Florian Huemer, κ.ά.
Έκδοση: (2021-01-01)

Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
ανά: Esther Lutgens, κ.ά.
Έκδοση: (2020-05-01)

Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma
ανά: Vafa Meftahpour, κ.ά.
Έκδοση: (2022-01-01)

Therapeutic Ultrasound-Enhanced Immune Checkpoint Inhibitor Therapy
ανά: Jinyun Yuan, κ.ά.
Έκδοση: (2021-03-01)

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
ανά: Naoki Hama, κ.ά.
Έκδοση: (2022-01-01)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
ανά: Akintunde Akinleye, κ.ά.
Έκδοση: (2019-09-01)

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
ανά: Naoki Hama, κ.ά.
Έκδοση: (2020-10-01)

From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer
ανά: Yibin Zhou, κ.ά.
Έκδοση: (2024-02-01)

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
ανά: Stephanie C. Pitts, κ.ά.
Έκδοση: (2024-05-01)

Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine
ανά: Pournima Kadam, κ.ά.
Έκδοση: (2020-11-01)

Immune checkpoint molecules in prevention and development of asthma
ανά: Zahra Kanannejad, κ.ά.
Έκδοση: (2023-02-01)

Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem
ανά: Esther Lutgens, κ.ά.
Έκδοση: (2021-06-01)

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
ανά: Jared M. Newton, κ.ά.
Έκδοση: (2019-08-01)

The Alcohol–High-Density Lipoprotein Athero-Protective Axis
ανά: Corina Rosales, κ.ά.
Έκδοση: (2020-07-01)

Immune checkpoint analysis in ear cancer
ανά: M. Klein, κ.ά.
Έκδοση: (2023-11-01)

Biomarkers for immune checkpoint blockers
ανά: Kirsty Wienand, κ.ά.
Έκδοση: (2018-06-01)

Immune Checkpoints in Viral Infections
ανά: Huiming Cai, κ.ά.
Έκδοση: (2020-09-01)

Immune checkpoint blockade in HIV
ανά: Celine Gubser, κ.ά.
Έκδοση: (2022-02-01)

Immune Checkpoint Inhibitors and the Heart
ανά: Diana Larisa Mocan-Hognogi, κ.ά.
Έκδοση: (2021-09-01)

Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process
ανά: E. Anglés-Cano
Έκδοση: (1997-11-01)

Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors
ανά: Zafer Gurel, κ.ά.
Έκδοση: (2024-10-01)

Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
ανά: Magalie Dosset, κ.ά.
Έκδοση: (2020-07-01)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
ανά: Mark P. Chao, κ.ά.
Έκδοση: (2020-01-01)

Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets
ανά: Xueyin Zhou, κ.ά.
Έκδοση: (2022-05-01)

Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression
ανά: Margaret A. McBride, κ.ά.
Έκδοση: (2021-02-01)

Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
ανά: Yujia Zhai, κ.ά.
Έκδοση: (2021-04-01)

Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
ανά: Nicholas Gravbrot, κ.ά.
Έκδοση: (2019-10-01)

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
ανά: Alice Mougel, κ.ά.
Έκδοση: (2019-03-01)

Editorial: Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer
ανά: Caroline E. Nunes-Xavier
Έκδοση: (2024-09-01)

Low HDL-C level is associated with the development of intracranial artery stenosis: analysis from the Chinese IntraCranial AtheroSclerosis (CICAS) study.
ανά: Yining Qian, κ.ά.
Έκδοση: (2013-01-01)

Editorial: The therapeutic inhibition of macrophage checkpoints
ανά: Alexandre P. A. Theocharides, κ.ά.
Έκδοση: (2024-04-01)

CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide.
ανά: Kuang-Yuh Chyu, κ.ά.
Έκδοση: (2012-01-01)